|
Abstract:
Jaundice occurs in most
newborn infants. Most jaundice is benign, but because of the potential
toxicity of bilirubin, newborn infants must be monitored to identify
those who might develop severe hyperbilirubinemia and, in rare
cases, acute bilirubin encephalopathy or kernicterus. The focus
of this guideline is to reduce the incidence of severe hyperbilirubinemia
and bilirubin encephalopathy while minimizing the risks of unintended
harm such as maternal anxiety, decreased breastfeeding, and unnecessary
costs or treatment. Although kernicterus should almost always be
preventable, cases continue to occur. These guidelines provide
a framework for the prevention and management of hyperbilirubinemia
in newborn infants of 35 or more weeks of gestation. In every infant,
we recommend that clinicians 1) promote and support successful
breastfeeding; 2) perform a systematic assessment before discharge
for the risk of severe hyperbilirubinemia; 3) provide early and
focused follow-up based on the risk assessment; and 4) when indicated,
treat newborns with phototherapy or exchange transfusion to prevent
the development of severe hyperbilirubinemia and, possibly, bilirubin
encephalopathy (kernicterus).
More resources:
AM Report PPT
AAP Handout on Jaundice
for Parents
GCN
InfoCard (includes Bhutani nomogram ©AAP)
NeoReview™ of transcutaneuos bilirubinometry
Case:
You are seeing a
2-month old infant in your practice who just moved to Texas
from Nevada. Where on the Internet can you go to determine what
newborn screening tests are routinely done in Nevada?
Answer:
National Newborn
Screening and Genetics Resource Center (click
above)
About NNSGRC:
Provides information and
resources about newborn screening and genetics for health professionals,
the public health community, consumers and government officials.
Provides information on
birth defects and surveillance.
|